Teva Announces tomy’s Award Winner at Oncology Satellite Symposium During the 7th International Symposium on Acute Promyelo...
October 05 2017 - 9:18AM
Business Wire
Best oral presenter Dr. Olga Salamero chosen as
the tomy’s winner. Research focused on treatments in elderly APL
patients
Teva Pharmaceuticals Europe BV, (NYSE and TASE: TEVA) announced
the winner of the tomy’s (Teva’s Orphan hematological Malignancies
award for Young hematologists) at the 7th International Symposium
on Acute Promyelocytic Leukemia (APL) in Rome, Italy last week.
During the event entitled, ‘Next-Generation APL Leaders: Teva’s
Award for Young Hematologists’ Dr. Salamero was awarded a tomy’s
trophy, as well as a bursary to attend the 2017 American Society of
Hematology (ASH) Annual Meeting, taking place in the USA in
December.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171005005748/en/
Dr. Olga Salamero presenting her research
during the Next-Generation APL Leaders Teva’s Award for Young
Hematologists in Rome, Italy (Photo: Business Wire)
Dr. Salamero is currently a hematologist at the Vall d’Hebron
University Hospital, Barcelona, Spain and presented research
entitled Very elderly acute promyelocytic leukemia: a multicentric
experience. The study selected patients aged ≥ 75 years old with
APL who had reported to PETHEMA registry (Spanish Hematology
Treatment Programme) over the last nineteen years. Epidemiologic
characteristics and disease features in the very elderly APL
population were analysed and the percentage of patients treated
according to investigators criteria described. The research found
that patients treated with all-trans retinoic acid (ATRA) plus
anthracycline-based regimen showed better outcomes than patients
who received other strategies, such as ATRA alone, chemotherapy
alone or best supportive care.
Speaking after the awards ceremony, Dr. Salamero said, “Winning
the tomy’s - it’s been a pleasure. I feel proud, not because of my
work but the work of the PETHEMA group. I would recommend attending
the APL Symposium as not only is it very interesting, but it
facilitates a lot and keeps you in touch with your peers.”
The tomy’s are an educational award programme for young
hematologists, sponsored by Teva Oncology. The awards are open to
young hematologists, or young physicians training to become
hematologists aged 40 years or younger. The entrants are challenged
to illustrate the latest scientific advancements in the management
of orphan hematological malignancies by presenting a case study or
case series demonstrating their excellence in education and
presentation skills. The independent jury for the 2017 tomy’s was
comprised of experts in orphan hematological malignancies and
includes Pierre Fenaux, France; Richard Schlenk, Germany; Francesco
Lo-Coco, Italy; Bob L�wenberg, Netherlands; Nigel Russell, UK and
Miguel Sanz, Spain.
“It’s estimated that between 1,500 – 2,000 people in Europe are
diagnosed with APL each year. Even though APL is the most lethal
type of acute leukemia, it’s highly curable and more research into
this disorder is urgently needed. The tomy’s programme reflects
Teva’s commitment to encouraging new and innovative research aimed
at improving patient outcomes in orphan hematological
malignancies,” said Paul Harmon, Head of Teva’s Oncology Care and
Transplant Europe.
“APL can cause a number of symptoms including uncontrollable
bleeding and can kill within hours or days if left untreated. As
it’s so rare, APL can be difficult to recognise and diagnose. We’re
excited about this programme, and we believe it will stimulate new
exciting research, with the ultimate ambition of saving lives,”
commented Prof. Lo-Coco, tomy jury member.
The full list of finalists as well as more information on the
jury can be accessed via: https://www.thinkapl.com/jury/
The tomy’s awards ceremony in Rome follows the inaugural tomy’s
awards, announced at the Teva Oncology Satellite Symposium at the
Acute Leukemias XVI International Symposium, which took place in
Munich, Germany, in February 2017.
For more information on the Tomy’s awards or for queries
regarding abstract submissions or notifications, please contact:
support@oncotomys.com.
-ENDS-
About Teva
Teva is among the top 15 global pharmaceutical companies
globally, delivering high-quality, patient-centric healthcare
solutions used by approximately 200 million patients in 60 markets
every day. Teva produces a leading innovative treatment for
multiple sclerosis and has late-stage development programs for a
range of disorders of the central nervous system, including
movement disorders, migraine, pain and neurodegenerative
conditions. With its European headquarters in Amsterdam, the
Netherlands, Teva is the world’s largest generic medicines
producer, leveraging its portfolio of more than 1,800 molecules to
produce a broad range of products in nearly every therapeutic area.
Teva draws on its specialty and generics capabilities to seek new
ways of addressing unmet patient needs by combining drug
development with devices, services and technologies. Teva's net
revenues in 2016 were $21.9 billion. For more information, visit
www.tevapharm.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171005005748/en/
TevaFiona Cohen+31 6 2008 2545orJayson Otke+31 6 8201
5407
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Sep 2023 to Sep 2024